Government Caps Trade Margins on 137 Cancer Drugs; Thiotepa Price Falls 91%, Patented Drugs Unchanged
How much it matters for each exam
- UPSC7/10
1At a glance
The National Pharmaceutical Pricing Authority's trade margin rationalisation policy has led to price cuts for some generic cancer drugs, with the highest reduction of 91% for Thiotepa. However, prices of all patented drugs like Pembrolizumab and Ribociclib remain unchanged, highlighting the policy's limitations in making cutting-edge therapies affordable.
Trade Margin Cap
The NPPA capped trade margins for 137 cancer drugs to rationalise prices, leading to revised MRPs for 543 formulations.
Patented Drugs Unaffected
Prices of all drugs under patent, like Pembrolizumab (Keytruda) and Ribociclib (Kisqali), remained unchanged, exposing a policy gap.
Mixed Impact
While Thiotepa's price fell 91%, 146 formulations saw no change, and 21 saw reductions of less than ₹100, showing limited overall impact.
2Facts to remember
Tap a card to see the answer. Try to recall it first.
3Detailed analysis
Context / Background
The National Pharmaceutical Pricing Authority (NPPA) regulates drug prices under the Drug Price Control Order (DPCO). To make cancer treatment affordable, it initiated a pilot project in 2019 for trade margin rationalisation, which has now been expanded to 137 cancer drugs. This policy aims to cap the margin between the price to stockists and the maximum retail price (MRP).
Core Analysis & Implications
The policy's impact is highly uneven. While generic chemotherapy drugs like Thiotepa saw a drastic 91% price cut, patented immunotherapy drugs (e.g., Pembrolizumab at ₹2.16 lakh/vial) saw zero reduction. This is because the margin cap applies to the first point of sale, not the manufacturing cost, allowing companies to inflate the base price. The policy fails to address the core issue of monopoly pricing for patented medicines, a major barrier to cancer care access in India.
Future Outlook / Way Forward
Experts, like K M Gopakumar, argue that for patented drugs, the government must utilise existing legal tools like compulsory licensing (under Section 92 of the Patents Act, 1970) to allow generic production and bring down prices. The debate highlights the tension between intellectual property rights and public health, a recurring theme in India's pharmaceutical policy.
4Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An independent body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for controlling the prices of drugs in India as per the Drugs (Prices Control) Order (DPCO).
- Trade Margin
- The difference between the price at which manufacturers sell to stockists/wholesalers and the Maximum Retail Price (MRP). Capping this margin aims to reduce the final price to consumers.
- Compulsory Licensing (Patents Act, 1970)
- A provision (under Sections 84 & 92) that allows the government to permit a third party to produce a patented product without the consent of the patent holder in certain circumstances, such as to address public health needs or if the drug is not available at a reasonably affordable price.
5How exams will ask this
- Data: 137 cancer drugs, 543 formulations, 91% price cut for Thiotepa.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Dept. of Pharmaceuticals.
- Legal Point: Compulsory Licensing under Sections 84/92 of the Patents Act, 1970.
Don't make this mistake!
They may ask about the 'number of drugs' (137) vs. 'number of formulations' (543). They might also swap the reason for unchanged patented drug prices (absence of competition) with other reasons like 'lack of government will' or 'high import duty'.
Write these in mains answers
Trade margin rationalisationPublic health vs. IPRAffordability of life-saving drugsLimitations of price control mechanisms
6Practice questions
Pick an answer, then read the explanation.
- Q1Hard
Consider the following statements regarding the recent cap on trade margins for cancer drugs:
- 1.The price cap led to a reduction in the Maximum Retail Price of all 543 formulations of the 137 selected drugs.
- 2.The policy was effective in reducing the prices of patented cancer drugs like Pembrolizumab and Ribociclib.
- 3.Experts suggest that compulsory licensing provisions under the Patents Act could be a more effective tool to make patented drugs affordable.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect as the article states prices remained unchanged for 146 formulations and saw minimal reductions for 21 others. Statement 2 is incorrect as the article explicitly states prices of all patented drugs remained unchanged. Statement 3 is correct as per the expert quoted in the article.
- Q2Medium
According to the news, what was the approximate average change in price across all the 543 formulations of cancer drugs after the trade margin cap?
Explanation: The article states: "The average change in prices, of all the formulations, stood at just over R5,000." The 'R' in the article denotes the Indian Rupee symbol (₹).
- Q3Medium
What is identified as a key limitation of the trade margin rationalisation policy for cancer drugs, as discussed in the article?
Explanation: The article quotes an expert saying trade margin rationalisation is unlikely to affect patent drug prices "in the absence of competition." This is the central critique, as companies can manipulate the first point of sale price, keeping final MRPs high despite the margin cap.
7All sources
Original28 October 2026 · Read story